Sclafani, Francesco
Brown, Gina
Cunningham, David
Wotherspoon, Andrew
Mendes, Larissa Sena Teixeira
Balyasnikova, Svetlana
Evans, Jessica
Peckitt, Clare
Begum, Ruwaida
Tait, Diana
Tabernero, Josep
Glimelius, Bengt
Roselló, Susana
Thomas, Janet
Oates, Jacqui
Chau, Ian
Article History
Received: 6 April 2017
Revised: 10 August 2017
Accepted: 22 August 2017
First Online: 21 September 2017
Competing interests
: DC received research funding from: Roche, Amgen, Celgene, Sanofi, Merck Serono, Novartis, AstraZeneca, Bayer, Merrimack and MedImmune. CP has had advisory roles with Sanofi. JT has had advisory roles with Amgen, Roche, Sanofi-Aventis, and Merck. IC has had advisory roles with Merck Serono, Roche, Sanofi Oncology, Bristol Myers Squibb, Eli-Lilly, Novartis, Gilead Science. He has received research funding from Merck-Serono, Novartis, Roche and Sanofi Oncology, and honoraria from Roche, Sanofi-Oncology, Eli-Lilly, Taiho. All other authors declare that they have no conflicts of interest.